A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety and Tolerability of AZD0530 in Patients With Advanced Solid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2016
At a glance
- Drugs Saracatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 13 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 13 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Dec 2010 Planned end date changed from 1 Dec 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.